Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.78 |
| ▸ | NAMPT | P43490 | 3/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GALR2 | O43603 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256955 | 1.00 | HDAC1 (0.78) | HDAC1NAMPTHDAC3HDAC2CYP1A2 | |
| SCHEMBL28410554 | 0.88 | HDAC1 (1.00) | HDAC1NAMPTHDAC3HDAC2RAB9A | |
| SCHEMBL28161757 | 0.87 | HDAC1 (0.73) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL16892137 | 0.84 | HDAC1 (1.00) | HDAC1NAMPTHDAC3HDAC2CYP3A4 | |
| SCHEMBL4261187 | 0.83 | HDAC1 (0.68) | HDAC1NAMPTHDAC3HDAC2CYP1B1 | |
| SCHEMBL4261184 | 0.83 | HDAC1 (0.68) | HDAC1NAMPTHDAC3HDAC2CYP1B1 | |
| SCHEMBL25722340 | 0.83 | HDAC1 (0.77) | HDAC1NAMPTHDAC3HDAC2MAPT | |
| SCHEMBL8255966 | 0.82 | HDAC1 (0.66) | HDAC1NAMPTHDAC3HDAC2CYP1A2 | |
| SCHEMBL13479662 | 0.81 | RAB9A (0.88) | CYP1A2CYP1A1CYP1B1MAPTKMT2A | |
| SCHEMBL24086662 | 0.81 | HDAC1 (0.79) | HDAC1NAMPTHDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC6 | HDAC1 1/4885NAMPT 214/4885HDAC3 5/4885 |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | HDAC1, AADAC, HDAC11 | HDAC1 1/4885NAMPT 351/4885HDAC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.